Metaxalone Shortage: What Providers and Prescribers Need to Know in 2026

Metaxalone (Skelaxin) is a centrally acting skeletal muscle relaxant that occupies a distinct niche in the muscle relaxant pharmacopeia: it's generally considered the least sedating option available, making it valuable for patients who need daytime functioning. However, its higher cost relative to alternatives like cyclobenzaprine and methocarbamol creates real-world prescribing and access challenges that providers need to understand in 2026.

This briefing covers the current availability landscape, prescribing implications, cost and access factors, and resources to help your patients access Metaxalone when it's the right clinical choice.

Current Availability Status

As of 2026, Metaxalone is not on the FDA's official drug shortage database. This distinguishes it from cyclobenzaprine, which has experienced pharmacy-level supply disruptions for certain strengths in 2025–2026. Multiple generic manufacturers produce Metaxalone, including Teva Pharmaceuticals and Lannett, and it is stocked by most major pharmacy chains.

That said, your patients may still report difficulty accessing Metaxalone. The access barriers are primarily driven by cost and formulary placement, not supply chain issues.

Formulary and Coverage Landscape in 2026

The primary access challenge for Metaxalone in 2026 is not supply — it's coverage. Providers should be aware of the following formulary realities:

• Tier placement. Generic Metaxalone is typically placed on Tier 2 or Tier 3 of commercial formularies, while cyclobenzaprine and methocarbamol are usually Tier 1. This means significantly higher patient cost-sharing for Metaxalone.
• Prior authorization. Some plans require prior authorization or step therapy (requiring a trial of cyclobenzaprine or methocarbamol first) before covering Metaxalone. For patients who have already failed or cannot tolerate alternatives, document this clearly in your notes to support PA submission.
• Medicare Part D. Coverage varies significantly by plan. Some Medicare Part D plans do not cover Metaxalone at any tier. Advise patients to check their specific plan formulary or use a discount card, as GoodRx and SingleCare pricing ($20–$25 for 30 tablets) may be lower than their Medicare negotiated rate.

Clinical Differentiation: When Is Metaxalone the Right Choice?

Research evidence suggests that skeletal muscle relaxants have comparable overall efficacy for acute musculoskeletal pain. The clinical differentiators are side effect profiles, drug interactions, controlled substance status, and cost. Metaxalone's principal clinical advantage is its lower sedation burden compared to cyclobenzaprine or carisoprodol. Consider Metaxalone preferentially for:

• Patients who drive professionally or operate machinery and must maintain cognitive function during the day
• Patients who have experienced excessive sedation with cyclobenzaprine
• Patients with conditions where anticholinergic burden should be minimized (unlike cyclobenzaprine, Metaxalone lacks significant anticholinergic activity)
• Patients who are not candidates for cyclobenzaprine due to cardiac rhythm concerns (cyclobenzaprine is structurally related to TCAs)

The 640 mg vs. 800 mg Prescribing Consideration

Providers should be aware of an important formulation issue: Metaxalone is available in two tablet strengths — 800 mg (standard, available as brand Skelaxin and generics) and 640 mg (generic-only). The FDA label explicitly states that these formulations are NOT substitutable on a milligram-for-milligram basis. They have different bioavailability characteristics, particularly in the fed vs. fasted state.

If a patient is being transitioned between strengths, follow the FDA-approved switch protocol: switch only in fasted state patients, and do not attempt mg-to-mg substitution. For most new prescriptions, specify 800 mg TID-QID to avoid formulary and dispensing confusion.

37,770+ patients found their medications in stock

37K+

Find Metaxalone In Stock Today →

Key Safety Reminders for Prescribers

• Serotonin syndrome risk. Metaxalone has been associated with serotonin syndrome, particularly when co-administered with SSRIs, SNRIs, TCAs, triptans, opioids (especially fentanyl, meperidine, methadone, tramadol), and MAO inhibitors. Screen carefully for serotonergic co-medications before prescribing.
• Hepatic and renal impairment. Metaxalone is contraindicated in severe hepatic or renal impairment. Use caution in mild-to-moderate impairment and monitor liver and renal function. Perform serial liver function tests in patients with pre-existing hepatic conditions.
• Hemolytic anemia. Metaxalone is contraindicated in patients with known tendency to drug-induced, hemolytic, or other anemias.
• Food effect. Taking Metaxalone with food significantly increases bioavailability and can enhance CNS depressant effects. Counsel patients to take it consistently — either always with or always without food — and be aware that elderly patients are especially susceptible to CNS effects when Metaxalone is taken with food.

Therapeutic Alternatives When Metaxalone Isn't Accessible

Systematic reviews have found insufficient evidence to determine the relative efficacy or safety superiority among skeletal muscle relaxants for acute musculoskeletal pain. When Metaxalone access is blocked by formulary or cost issues, consider these clinical alternatives:

• Methocarbamol (Robaxin): 1,500 mg QID initially, then 750–1,000 mg TID-QID. Not on Beers Criteria. Tier 1 on most formularies. Well tolerated. Good option if sedation is a concern and Metaxalone is unavailable.
• Cyclobenzaprine (Flexeril): 5–10 mg TID or 15–30 mg ER once daily. Most affordable; Tier 1 on most formularies. More sedating; avoid in patients 65+ (Beers Criteria). Cardiac caution due to TCA-like structure.
• Tizanidine (Zanaflex): 2–4 mg Q6–8H. Alpha-2 agonist. Useful when both antispasmodic and antispastic effects are needed. Requires LFT monitoring. Contraindicated with fluvoxamine and ciprofloxacin.

Skip the calls, skip the stress.

Find Metaxalone In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Tools to Help Your Patients Access Metaxalone

When Metaxalone is the right clinical choice but your patient is struggling to fill their prescription, medfinder for Providers is a practical resource. medfinder calls pharmacies near your patient's location to identify which ones have Metaxalone in stock and can fill the prescription. The patient receives the results by text, eliminating the frustrating process of calling pharmacy after pharmacy.

Additionally, advise patients without adequate insurance coverage to use GoodRx or SingleCare discount cards. The discounted price (approximately $20–$25 for 30 tablets) is often significantly lower than what they'd pay using their Medicare Part D card.

Summary for Prescribers

Metaxalone remains a valuable option — particularly for its low sedation profile — but its cost and formulary position create access barriers that fall disproportionately on uninsured and Medicare patients. Proactive prescribing means documenting the clinical rationale for Metaxalone selection, being prepared to submit prior authorizations, and having a ready alternative if access is blocked. For a step-by-step guide to helping your patients find Metaxalone in stock, see our provider guide to finding Metaxalone.